Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 301–400 of 1,000
Intestinal and Hepatic Niemann-Pick C1-Like 1
Park, S. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.4.240 · Cited by 37
“However, a 2-year clinical trial, Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) shows no distinct change of carotid intima-media thickness between coadministration of ezetimibe and simvastatin and simvastatin alone in 720 heterozygous familial hypercholesterolemic pati…”
BackgroundBattaggia, A., Donzelli, A., Font, M., Molteni, D., & Galvano, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124587 · Cited by 36
Management of the Patient with Statin Intolerance
Vandenberg, B. F., & Robinson, J. G. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0077-8 · Cited by 40
“The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial found no benefit on carotid intimal medial thickness (CIMT) progression from an additional17%reductioninLDL-Cusing80mgofsimvastatinina 24-month trial of patients with familial hypercholesterolemia [ 31 ].”
BackgroundRole for Combination Therapy in Diabetic Dyslipidemia
Warraich, H. J., Wong, N. D., & Rana, J. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0589-5 · Cited by 41
Recent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 42
Krysiak, R. G., & Okopień, B. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318211703b · Cited by 36
“After 90 d 46 (3) [22] 48 (3) [3] 48 (3) [5] 54 (4) [17]*†”
Mondello, S., & Hayes, R. L. (2015) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52892-6.00016-7 · Cited by 38
Update on the efficacy and safety of combination ezetimibe plus statin therapy
Toth, P. P., Catapano, A. L., Tomassini, J. E., & Tershakovec, A. M. (2010) · Clinical Lipidology · doi:10.2217/clp.10.49 · Cited by 35
Page, M. M., Bell, D. A., Hooper, A. J., Watts, G. F., & Burnett, J. R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.004 · Cited by 39
van den Oord, S. C. H., Akkus, Z., van Lennep, J. E. R., Bosch, J. G., van der Steen, A. F. W., Sijbrands, E. J. G., & Schinkel, A. F. L. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.040 · Cited by 35
Self-citationPharmacological Options in Atherosclerosis: A Review of the Existing Evidence
Gupta, K. K., Ali, S., & Sanghera, R. S. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0123-0 · Cited by 41
Kouvelos, G. N., Arnaoutoglou, E. M., Matsagkas, M. I., Kostara, C., Gartzonika, C., Bairaktari, E. T., & Milionis, H. J. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248412445506 · Cited by 35
Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy
Aberg, J. A. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.009 · Cited by 35
Alsheikh-Ali, A. A. A., & Karas, R. H. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.02.005 · Cited by 35
Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets
Brie, D. M., Mornoş, C., Adam, O., Tîrziu, A., Popescu, R., & Brie, A. D. (2025) · Cells · doi:10.3390/cells15010072 · Cited by 34
“This result suggests an additional mechanism, possibly independent of LDL-C [171].”
Peters, S. A. E., den Ruijter, H. M., & Bots, M. L. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11591960-000000000-00000 · Cited by 37
Self-citationDyslipidemia: Management Using Optimal Lipid-Lowering Therapy
Ito, M. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r127 · Cited by 39
Lamprea-Montealegre, J. A., Astor, B. C., McClelland, R. L., de Boer, I. H., Burke, G. L., Sibley, C. T., O’Leary, D., Sharrett, A. R., & Szklo, M. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02090212 · Cited by 34
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 38
Self-citationFamilial hypercholesterolemia: experience from the French-Canadian population
Paquette, M., Genest, J. J., & Baass, A. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000487 · Cited by 37
Zheng, K. H., Kaiser, Y., van Olden, C. C., Santos, R. D., Dasseux, J., Genest, J. J., Gaudet, D., Westerink, J., Keyserling, C., Verberne, H. J., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.004 · Cited by 34
Self-citationAnti-Inflammatory Activity of Ezetimibe by Regulating NF-κB/MAPK Pathway in THP-1 Macrophages
Li, Q., Yang, Y., Yang, Y., Zhu, N., Li, S., Liao, D., & Zheng, X. (2014) · Pharmacology · doi:10.1159/000357953 · Cited by 34
Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop
Bai, J. P. F., Bell, R., Buckman, S., Burckart, G. J., Eichler, H.-G., Fang, K. C., Goodsaid, F. M., Jusko, W. J., Lesko, L. L., Meibohm, B., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9265-x · Cited by 35
de Araújo, D. B., Bertolami, M. C., Ferreira, W. P., Abdalla, D. S. P., Faludi, A. Á., Nakamura, Y., & Bricharello, L. P. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181bfb1a2 · Cited by 34
“simvastatin alone on the atherosclerotic process in patients with heterozygous familial hypercholesterolemia trial and the simvastatin and ezetimibe in aortic stenosis trials, the benefits of ezetimibe were not clear.(35,36) On the other hand, stop atherosclerosis in native diabetics study trial showed that ezetimibe…”
BackgroundThe HALTS Trial — Halting Atherosclerosis or Halted Too Early?
Blumenthal, R. S., & Michos, E. D. (2009) · New England Journal of Medicine · doi:10.1056/nejme0908838 · Cited by 34
IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease
Catapano, A. L., & Ference, B. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.008 · Cited by 36
C‐reactive protein lowering with rosuvastatin in the METEOR study
Peters, S. A. E., Palmer, M. K., Grobbee, D. E., Crouse, J. R., O’Leary, D. H., Raichlen, J. S., & Bots, M. L. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02230.x · Cited by 33
Self-citationStauffer, M. E., Weisenfluh, L., & Morrison, A. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s52713 · Cited by 33
Chokshi, D. A., Avorn, J., & Kesselheim, A. S. (2010) · Health Affairs · doi:10.1377/hlthaff.2010.0843 · Cited by 35
Salami, J. A., Warraich, H. J., Valero‐Elizondo, J., Spatz, E. S., Desai, N. R., Rana, J. S., Virani, S. S., Blankstein, R., Khera, A., Blaha, M. J., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007132 · Cited by 33
Ibrahim, S., Reeskamp, L. F., de Goeij, J. N., Hovingh, G. K., Planken, R. N., Bax, W. A., Min, J. K., Earls, J. P., Knaapen, P., Wiegman, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae028 · Cited by 34
Self-citationCholesterol-lowering phytosterols: factors affecting their use and efficacy
Carr (2010) · Nutrition and Dietary Supplements · doi:10.2147/nds.s10974 · Cited by 38
Hyperlipidemia in Older Adults
Aslam, F., Haque, A., Lee, L. V., & Foody, J. M. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.08.001 · Cited by 36
“not result in greater changes in carotid intima-media thickness compared with simvastatin alone, despite significantly greater reductions in LDL cholesterol and CRP.(58)”
A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
Alla, V. M., Agrawal, V., DeNazareth, A., Mohiuddin, S., Ravilla, S., & Rendell, M. (2013) · Drugs · doi:10.1007/s40265-013-0072-9 · Cited by 34
“A similar failure occurred in familial hypercholesterolemic patients in the ENHANCE Trial, despite lower LDL levels in the ezetimibe plus simvastatin group [38].”
ResultFlorentin, M., Liberopoulos, E. N., Moutzouri, E., Rizos, C. V., Tselepis, A. D., & Elisaf, M. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.546394 · Cited by 33
Bos, S., Duvekot, M. H. C., ten Kate, G. R., Verhoeven, A. J. M., Mulder, M. T., Schinkel, A. F. L., Nieman, K., Watts, G. F., Sijbrands, E. J. G., & van Lennep, J. E. R. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.12.005 · Cited by 33
Self-citationDefining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia
Ferreira, A. M., & da Silva, P. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0205-0 · Cited by 35
“come, the change from baseline mean cIMT [54].”
BackgroundO’Gorman, C. S., Conwell, L. S., & O‘Neill, M. F. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s7356 · Cited by 32
Kostapanos, M. S., Spyrou, A., Tellis, C. C., Gazi, I. F., Tselepis, A. D., Elisaf, M., & Liberopoulos, E. N. (2011) · Lipids · doi:10.1007/s11745-011-3539-z · Cited by 32
The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?
Rizzo, M., Rini, G. B., Spinas, G. A., & Berneis, K. K. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.005 · Cited by 32
New Approaches in Detection and Treatment of Familial Hypercholesterolemia
Hartgers, M. L., Ray, K. K., & Hovingh, G. K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0665-x · Cited by 37
Therapeutic strategies to deplete macrophages in atherosclerotic plaques
Meyer, I. D., Martinet, W., & Meyer, G. R. Y. D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04211.x · Cited by 35
Evaluation and management of hyperlipidemia in children and adolescents
Iughetti, L., Bruzzi, P., & Predieri, B. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32833ab869 · Cited by 37
Is the Carotid Intima-Media Thickness Really a Good Surrogate Marker of Atherosclerosis?
Tran, L., Park, H., & Kim, H.-D. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11767 · Cited by 32
Carotid Intima-Media Thickness Studies: Study Design and Data Analysis
Peters, S. A. E., & Bots, M. L. (2013) · Journal of Stroke · doi:10.5853/jos.2013.15.1.38 · Cited by 40
Self-citationEffects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
Yamaoka‐Tojo, M., Tojo, T., Kosugi, R., Hatakeyama, Y., Yoshida, Y., Machida, Y., Aoyama, N., Masuda, T., & Izumi, T. (2009) · Lipids in Health and Disease · doi:10.1186/1476-511x-8-41 · Cited by 33
Haghbin, H., Gangwani, M. K., Ravi, S. J. K., Perisetti, A., Aziz, M., Goyal, H., Nawras, A., & Sodeman, T. (2020) · Annals of Gastroenterology · doi:10.20524/aog.2020.0550 · Cited by 34
“Moreover, although lipid-lowering effects were observed, the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) RCT with 720 familial hypercholesterolemia patients, failed to show an improvement in carotid artery intima-media thickness (a surrogate of atherosclerosis) in fa…”
BackgroundPlans-Rubió, P. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/11539150-000000000-00000 · Cited by 31
The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin
Shaw, S. M., Chaggar, P., Ritchie, J., Shah, M. K. H., Baynes, A. C., O’Neill, N., Fildes, J. E., Yonan, N., & Williams, S. G. (2009) · Transplantation · doi:10.1097/tp.0b013e318198d7d0 · Cited by 31
“The benefit of LDL lowering by ezetimibe has recently been brought under question following the results of the ENHANCE study (20).”
Farnier, M., Bruckert, É., Boileau, C., & Krempf, M. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.01.053 · Cited by 34
“Le second essai (ENHANCE) [56] a évalué l’effet de l’addition d’ézétimibe 10 mg à la simvastatine 80 mg.”
BackgroundPeters, S. A. E., den Ruijter, H. M., Palmer, M. K., Grobbee, D. E., Crouse, J. R., O’Leary, D. H., Evans, G., Raichlen, J. S., Lind, L., Bots, M. L., et al. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02422.x · Cited by 31
Self-citationLeveraging human genetics to guide drug target discovery
Stitziel, N. O., & Kathiresan, S. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.08.008 · Cited by 31
“there was substantial uncertainty over whether or not ezetimibe would reduce clinical CHD[34, 35].”
Mariano, C., Alves, A. C., Medeiros, A. M., Chora, J. R., Antunes, M. C. D. S., Futema, M., Humphries, S. E., & Bourbon, M. (2020) · Clinical Genetics · doi:10.1111/cge.13697 · Cited by 34
“Untreated TG, HDL-C and apoA1 values were not estimated, because the effects of lipid-lowering therapy with statins are not significant on these traits.(32,33)”
BackgroundMasson, W. M., Lobo, M., Siniawski, D. A., Molinero, G., Masson, G., Huerin, M. S., & Nogueira, J. P. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01297-5 · Cited by 31
Ezetimibe-related myopathy: A systematic review
Slim, H. B., & Thompson, P. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.08.430 · Cited by 32
Kater, A. L. D. A., Batista, M. C., & Ferreira, S. R. G. (2010) · Metabolism · doi:10.1016/j.metabol.2010.02.011 · Cited by 31
Atherosclerosis: Current Status of Prevention and Treatment
Whayne, T. F. (2011) · International Journal of Angiology · doi:10.1055/s-0031-1295520 · Cited by 37
“Much controversy has emerged on the use of ezetimibe in achieving this low LDL goal but there is no question that it contributes significant additional LDL reduction.(26) Nevertheless, outcome studies with ezetimibe use are still lacking.”
BackgroundTimbie, J. W., Hayward, R. A., & Vijan, S. S. (2010) · Health Services Research · doi:10.1111/j.1475-6773.2009.01075.x · Cited by 35
Millar, J. S., & Lagor, W. R. (2009) · Journal of Receptor Ligand and Channel Research · doi:10.2147/jrlcr.s6033 · Cited by 40
“103 This has been associated with a decrease in LDL cholesterol levels of 18% alone and by 53% when used in combination with a statin 104 since these drugs act to lower LDL levels through complimentary mechanisms.”
Surrogate markers, atherosclerosis and cardiovascular disease prevention
Wierzbicki, A. S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01794.x · Cited by 31
Lavie, C. J., Milani, R. V., & O’Keefe, J. H. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821483fa · Cited by 30
Moneta, G. L. (2009) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(09)79141-9 · Cited by 30
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 32
High Cholesterol Disorders, Myocardial Infarction and Its Therapeutics
Upadhyay, R. K. (2023) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2023.138040 · Cited by 30
Peters, S. A. E., den Ruijter, H. M., Grobbee, D. E., & Bots, M. L. (2012) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.978114 · Cited by 32
Self-citationNochioka, K., Tanaka, S.-I., Miura, M., Do.e, Z., Fukumoto, Y., Shiba, N., & Shimokawa, H. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0331 · Cited by 30
Peters, S. A. E., den Ruijter, H. M., Palmer, M. K., Grobbee, D. E., Crouse, J. R., O’Leary, D. H., Evans, G. W., Raichlen, J. S., & Bots, M. L. (2011) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2011.09.009 · Cited by 33
Self-citationLee, J., Egolum, U. O., Parihar, H. S., Cooley, M., & Ling, H. (2021) · Cardiology Research · doi:10.14740/cr1224 · Cited by 31
“In the ENHANCE trial [26], ezetimibe added to background therapy of simvastatin 80 mg daily demonstrated an additional reduction in LDL-C levels by 16.”
MethodMa, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 31
Hu, X., Steffensen, K. R., Jiang, Z. ‐., Parini, P., Gustafsson, J.-Α., Gåfvels, M. E., & Eggertsen, G. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02529.x · Cited by 34
Ye, Y., Zhao, X., Zhai, G., Guo, L.-L., Tian, Z., & Zhang, S. (2012) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248412449384 · Cited by 30
“Ezetimibe in Aortic Stenosis (SEAS) studies.(10,11) The latest Study of Heart and Renal Protection trail proved that reduction in LDL-C with 20 mg of simvastatin plus 10 mg of ezetimibe administered daily safely resulted in reduced incidence of major atherosclerotic events in a wide range of patients with advanced chr…”
Liu, Z., Hao, H., Yin, C., Chu, Y., Li, J., & Xu, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15078 · Cited by 30
“But some other trails didn’t support this conclusion [36, 37].”
ResultPedrinelli, R. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4800 · Cited by 30
McCormack, J. P., & Allan, G. M. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000196 · Cited by 32
Harchaoui, K. E., Akdim, F., Stroes, E. S. G., Trip, M. D., & Kastelein, J. J. P. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808040-00003 · Cited by 32
Self-citationWest, A. M., Anderson, J. D., Epstein, F. H., Meyer, C. H., Wang, H., Hagspiel, K. D., Berr, S. S., Harthun, N. L., WELTMAN, A. L., DiMaria, J. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.034 · Cited by 30
Intestinal sterol transporters and cholesterol absorption inhibition
Davis, H. R., Tershakovec, A. M., Tomassini, J. E., & Musliner, T. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834c7c28 · Cited by 28
Doneen, A. L., & Bale, B. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.03.2645 · Cited by 35
Mendelian randomization: Its impact on cardiovascular disease
Kawashiri, M., Tada, H., Nomura, A., & Yamagishi, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.04.007 · Cited by 29
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs
Gupta, A., Guyomard, V., Zaman, M., Rehman, H. U., & Myint, P. K. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0033-6 · Cited by 35
Ikeda, K., Takahashi, T., Yamada, H., Matsui, K., Sawada, T., Nakamura, T., Matsubara, H., & (for the PEACE Investigators) (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312451539 · Cited by 28
Mangat, R., Warnakula, S., Borthwick, F., Hassanali, Z., Uwiera, R. R. E., Russell, J. C., Cheeseman, C. I., Vine, D. F., & Proctor, S. D. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003434 · Cited by 30
“Some clinical trials have demonstrated that ezetimibe in combination with simvastatin can reduce carotid intima-media thickness,(15) whereas other trials have shown that addition of ezetimibe to the lipid-lowering regimen does not reduce carotid intima-media thickness.(16) Still, the effect of these compounds on acute…”
The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?
Ridker, P. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.168989 · Cited by 32
Olyaei, A. J., Greer, E., Santos, R. D., & Rueda, J. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09091010 · Cited by 27
“Alone on Atherosclerosis in the Carotid Artery), despite decreases in levels of LDL cholesterol and C-reactive protein, combined therapy with ezetimibe and simvastatin did not show clinically or statically significant differences in changes in intima-media thickness, as compared with simvastatin alone (37).”
ResultPharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
Choi, J. Y., & Na, J. O. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.183 · Cited by 23
Approach to the diagnosis and management of lipoprotein disorders
Al-Waili, K., Al‐Rasadi, K., Awan, Z. A., & Genest, J. J. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328329135a · Cited by 27
Kennedy, M. J., Jellerson, K. D., Snow, M. Z., & Zacchetti, M. L. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0028-2 · Cited by 27
“Although ezetimibe effectively lowers LDL cholesterol when used both alone and in combination with a statin in adults, its clinical benefit on cardiovascular risk reduction has yet to be proven [12].”
BackgroundThe efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups
Catapano, A. L., Toth, P. P., Tomassini, J. E., & Tershakovec, A. M. (2013) · Clinical Lipidology · doi:10.2217/clp.12.88 · Cited by 28
Pauriah, M., Elder, D. H. J., Ogston, S. A., Noman, A., Majeed, A., Wyatt, J. C., Choy, A. M., MacDonald, T. M., Struthers, A. D., & Lang, C. C. (2014) · Heart · doi:10.1136/heartjnl-2013-304678 · Cited by 28
Matsue, Y., Matsumura, A., Suzuki, M., Hashimoto, Y., & Yoshida, M. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0033 · Cited by 28
Sun, D., Gui, X., Wang, J., Li, Y., Mei, S., Ding, H., & Yan, J. (2020) · Epigenomics · doi:10.2217/epi-2020-0155 · Cited by 27
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 27
“1 %, respectively, in the combined therapy group [164].”
BackgroundDyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
“The trial showed that ezetimibe in combination with simvastatin did not significantly change the mean carotid artery intima-media thickness in patients with FH [54].”
Backgroundvan Wijk, D. F., Strang, A. C., Duivenvoorden, R., Enklaar, D.-J. F., van der Geest, R. J., Kastelein, J. J. P., de Groot, E., Stroes, E. S. G., & Nederveen, A. J. (2013) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-013-0407-2 · Cited by 28
“Participants Using previously described echo duplex measurements [2,5], consecutive individuals with one or more atherosclerotic events were screened for the presence of significant atherosclerotic disease in one of the carotid arteries.”
BackgroundMethodSelf-citationImpact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?
Badarin, F. J. A., Kullo, I. J., Kopecky, S. L., & Thomas, R. J. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60545-4 · Cited by 27
Barbosa, S. P., Lins, L. C., Fonseca, F. A. H., de Matos, L. N., Aguirre, A. C. C., Bianco, H. T., do Amaral, J. B., França, C. N., Santana, J. M., & Izar, M. C. D. O. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.02.018 · Cited by 26
Quantitative detection of free 24S-hydroxycholesterol, and 27-hydroxycholesterol from human serum
Bandaru, V. V. R., & Haughey, N. J. (2014) · BMC Neuroscience · doi:10.1186/s12868-014-0137-z · Cited by 26
“A number of sterol modifying agents are being tested as potential therapeutics for neurodegenerative disease [46-52], and it is possible that serum measures of 24S-hydroxycholesterol and 27-hydroxycholesterol may have utility as rapid and inexpensive surrogate markers to efficiently determine the effectiveness of ther…”
BackgroundShifting views on lipid lowering therapy
Krumholz, H. M., & Hayward, R. A. (2010) · BMJ · doi:10.1136/bmj.c3531 · Cited by 27
“Other interventions, such as the use of oestrogen, clofibrate, and dextrothyroxine, reduce LDL cholesterol but do not reduce risk. Most recently, questions are being raised about ezetimibe, which effectively reduces LDL but has not been shown to improve patient outcomes; trial evidence has raised questions about its s…”
BackgroundGreenberg, M. E., Smith, J. D., & Sehayek, E. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.194605 · Cited by 27
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease
Bittner, V., Deng, L., Rosenson, R. S., Taylor, B., Glasser, S. P., Kent, S. T., Farkouh, M. E., & Muntner, P. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.042 · Cited by 26
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.